During the last session, Cytosorbents Corp (NASDAQ:CTSO)’s traded shares were 0.41 million, with the beta value of the company hitting 0.58. At the end of the trading day, the stock’s price was $1.01, reflecting an intraday gain of 13.36% or $0.12. The 52-week high for the CTSO share is $2.15, that puts it down -112.87 from that peak though still a striking 30.69% gain since the share price plummeted to a 52-week low of $0.70. The company’s market capitalization is $55.37M, and the average intraday trading volume over the past 10 days was 0.12 million shares, and the average trade volume was 128.16K shares over the past three months.

Cytosorbents Corp (NASDAQ:CTSO) trade information

Cytosorbents Corp (CTSO) registered a 13.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.36% in intraday trading to $1.01, hitting a weekly high. The stock’s 5-day price performance is 10.68%, and it has moved by 9.08% in 30 days. Based on these gigs, the overall price performance for the year is -42.29%. The short interest in Cytosorbents Corp (NASDAQ:CTSO) is 1.37 million shares and it means that shorts have 9.57 day(s) to cover.

Cytosorbents Corp (CTSO) estimates and forecasts

Statistics show that Cytosorbents Corp has outperformed its competitors in share price, compared to the industry in which it operates. Cytosorbents Corp (CTSO) shares have gone up 20.07% during the last six months, with a year-to-date growth rate more than the industry average at 53.13% against 11.20. In the rating firms’ projections, revenue will increase 5.99% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.45M as predicted by 3 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 10.09M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 8.67M and 9.79M respectively. In this case, analysts expect current quarter sales to grow by 9.05% and then jump by 3.08% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.64%. While earnings are projected to return 53.12% in 2024.

CTSO Dividends

Cytosorbents Corp is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Cytosorbents Corp (NASDAQ:CTSO)’s Major holders

Cytosorbents Corp insiders own 3.81% of total outstanding shares while institutional holders control 33.29%, with the float percentage being 34.61%. AVENIR CORP is the largest shareholder of the company, while 63.0 institutions own stock in it. As of 2024-06-30, the company held over 2.97 million shares (or 5.4738% of all shares), a total value of $2.09 million in shares.

The next largest institutional holding, with 2.84 million shares, is of SKYLANDS CAPITAL, LLC’s that is approximately 5.2352% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.0 million.

Also, the Mutual Funds coming in first place with the largest holdings of Cytosorbents Corp (CTSO) shares are Vanguard Total Stock Market Index Fund and Neuberger & Berman Intrinsic Value Fd . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.3 shares. This amounts to just over 2.38 percent of the company’s overall shares, with a $1.32 million market value. The same data shows that the other fund manager holds slightly less at 726.14, or about 1.33% of the stock, which is worth about $0.73 million.